Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

Figure 2

PR-104-induced neutropenia followed until death or further treatment. (a) Time-course of neutropenia in each subject at 135 mg/m2 (b) ime-course of neutropenia in each subject at 240 mg/m2 (c) Time-course of neutropenia in each subject at 540 mg/m2 (d) Time-course of neutropenia in each subject at 675 mg/m2 (e) Time-course of neutropenia in each subject at 900 mg/m2 (f) Neutrophil nadir on first treatment cycle correlated with PR-104 dose-level (Spearman r = -0.56; P < 0.005)

Back to article page